Moderna Inc (MRNA) faced notable selling pressure during today’s trading session, closing at $218.01 after a significant drop of 7.82%. The stock’s intraday movement reflected a low of $214.74 and a high of $221.28, illustrating the volatility as it struggled against the broader market’s downward trend.
While the S&P 500 slipped 1.11% to finish at $763.25 and the Dow Jones Industrial Average eased 0.40% to $519.10, Moderna’s performance stood out as a laggard. Competitor AbbVie (ABBV) edged higher by 0.71% to $285.42, highlighting a stark divergence between Moderna’s struggles and its industry peers. This relative weakness may be attributed to sector-specific pressures and a general risk-off sentiment weighing heavily on biotechnology stocks.
Currently, Moderna’s stock is trading approximately 10.0% below its 52-week high of $242.29, with a range over the past year spanning from $22.28 to $242.29. The trading volume was robust at 18.96 million shares, suggesting that investors are actively adjusting their positions, potentially in response to profit-taking near resistance levels or a broader consolidation off recent highs.